6669 Stock Overview
Operates as an interventional medical device company that offers vascular interventional treatment products in Mainland China, Europe, and internationally. More details
| Snowflake Score | |
|---|---|
| Valuation | 0/6 |
| Future Growth | 5/6 |
| Past Performance | 1/6 |
| Financial Health | 5/6 |
| Dividends | 0/6 |
Acotec Scientific Holdings Limited Competitors
Price History & Performance
| Historical stock prices | |
|---|---|
| Current Share Price | HK$7.19 |
| 52 Week High | HK$12.44 |
| 52 Week Low | HK$5.80 |
| Beta | 0.21 |
| 11 Month Change | -3.10% |
| 3 Month Change | -4.13% |
| 1 Year Change | -40.87% |
| 33 Year Change | -47.52% |
| 5 Year Change | n/a |
| Change since IPO | -59.15% |
Recent News & Updates
Recent updates
An Intrinsic Calculation For Acotec Scientific Holdings Limited (HKG:6669) Suggests It's 46% Undervalued
Mar 21
We Think Acotec Scientific Holdings (HKG:6669) Can Easily Afford To Drive Business Growth
Nov 17Acotec Scientific Holdings Limited's (HKG:6669) Intrinsic Value Is Potentially 42% Above Its Share Price
Oct 20Acotec Scientific Holdings (HKG:6669) Has More To Do To Multiply In Value Going Forward
Sep 24An Intrinsic Calculation For Acotec Scientific Holdings Limited (HKG:6669) Suggests It's 49% Undervalued
Jul 01Shareholder Returns
| 6669 | HK Medical Equipment | HK Market | |
|---|---|---|---|
| 7D | -1.6% | -3.5% | -0.6% |
| 1Y | -40.9% | -39.2% | 9.6% |
Return vs Industry: 6669 underperformed the Hong Kong Medical Equipment industry which returned -39.2% over the past year.
Return vs Market: 6669 underperformed the Hong Kong Market which returned 9.6% over the past year.
Price Volatility
| 6669 volatility | |
|---|---|
| 6669 Average Weekly Movement | 8.0% |
| Medical Equipment Industry Average Movement | 9.9% |
| Market Average Movement | 8.9% |
| 10% most volatile stocks in HK Market | 19.2% |
| 10% least volatile stocks in HK Market | 4.3% |
Stable Share Price: 6669 has not had significant price volatility in the past 3 months compared to the Hong Kong market.
Volatility Over Time: 6669's weekly volatility (8%) has been stable over the past year.
About the Company
| Founded | Employees | CEO | Website |
|---|---|---|---|
| 2011 | 615 | Jing Li | www.acotec.cn |
Acotec Scientific Holdings Limited operates as an interventional medical device company that offers vascular interventional treatment products in Mainland China, Europe, and internationally. The company’s products include AcoArt Orchid & Dhalia, a paclitaxel DCB used to prevent stenosis or occlusion in superficial femoral artery (SFA) and popliteal artery (PPA) for the treatment of lower extremity artery disease (LEAD) with a vascular interventional approach; and AcoArt Tulip & Litos, a paclitaxel coated DCB used to prevent stenosis or occlusion in below-theknee (BTK) arteries for the treatment of chronic limb-threatening ischemia with a vascular interventional approach. It also offers devices targeting vascular surgery, including AcoArt Iris & Jasmin; AcoArt Lily & Rosmarin; Peripheral Aspiration System (AcoStream); Radiofrequency Ablation System (AcoArt Cedar); Peripheral Support Catheter (Vericor); The PTA Balloon (P-Conic); and 2nd Gen Peripheral Aspiration System (2nd Generation AcoStream).
Acotec Scientific Holdings Limited Fundamentals Summary
| 6669 fundamental statistics | |
|---|---|
| Market cap | HK$2.25b |
| Earnings (TTM) | HK$34.46m |
| Revenue (TTM) | HK$562.02m |
65.4x
P/E Ratio4.0x
P/S RatioIs 6669 overvalued?
See Fair Value and valuation analysisEarnings & Revenue
| 6669 income statement (TTM) | |
|---|---|
| Revenue | CN¥523.12m |
| Cost of Revenue | CN¥123.62m |
| Gross Profit | CN¥399.51m |
| Other Expenses | CN¥367.43m |
| Earnings | CN¥32.08m |
Last Reported Earnings
Jun 30, 2024
Next Earnings Date
n/a
| Earnings per share (EPS) | 0.10 |
| Gross Margin | 76.37% |
| Net Profit Margin | 6.13% |
| Debt/Equity Ratio | 4.1% |
How did 6669 perform over the long term?
See historical performance and comparison